TY - JOUR ID - 46744 TI - Toward an Alum Free Mono-Component Monovalent Pertussis Vaccine: A Cytokine Response Assay JO - Iranian Journal of Immunology JA - IJI LA - en SN - 1735-1383 AU - Forghani, Hossein AU - Jamshidi Makiani, Mahin AU - Zarei Jaliani, Hossein AU - Zahraei, Seyed Mohsen AU - Namayandeh, Seyedeh Mahdieh AU - Khani, Parisa AD - 1. Antimicrobial Resistance Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran. 2. Department of Public Health, Faculty of Health, Shahid Sadoughi University of Medical AD - Antimicrobial Resistance Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran. AD - Protein Engineering Laboratory, Department of Medical Biotechnology, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. AD - Infectious Disease Center for Communicable Disease Control, Ministry of Health and Medical Education, Iran. AD - Statistic and Epidemiology Department, Health Faculty, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. AD - Research and Clinical Center for Infertility, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Y1 - 2020 PY - 2020 VL - 17 IS - 2 SP - 111 EP - 120 KW - Fusion Protein KW - Listeriolysin O KW - LLO-PTS1 KW - PST1 KW - Pertussis KW - Vaccine DO - 10.22034/iji.2020.86199.1749 N2 - Background: Currently evidence indicates the resurgence of whooping cough despite high coverage of whole-cell (wP) and acellular (aP) pertussis vaccines. Objective: In this study, we investigated the cell-mediated immune response of a genetically inactivated protein containing the S1 subunit of pertussis toxin (PTS1) without and with the Listeriolysin O (LLO-PTS1), developed by the researchers (the authors of this study), in comparison with current wP and aP vaccines in the mice model. Methods: Thirty-six female NMRI mice aged 8 to 12 weeks (25 ± 5 g) were divided into six groups including control (n=6), and five treated groups (n=6/each). Treated groups comprising recombinant PTS1, recombinant fusion LLO-PTS1, aP, wP, and sham (phosphate-buffered saline) were injected intraperitoneally whereas the control group did not receive anything. After 60 days, the serum levels of IFN-γ, IL-4, and IL-17 cytokines (as the T-helper 1, 2, and 17 responses, respectively) were evaluated by mouse ELISA Kit. Results: Our findings showed LLO-PTS1 significantly increased IL-17 and IL-4 cytokines compared with wP and aP vaccines (superiority). IFN-γ failed to significantly increase in the LLO-PTS1 group compared to others but it was non-inferior to standard vaccines (non-inferiority). Conclusion: Our alum free mono-component monovalent recombinant fusion protein (LLO-PTS1), registered as a patent in the www.iripo.ssaa.ir, could bear the capacity to stimulate the Th-1 response similar to wP and aP vaccines (non-inferiority) in the mice model. In addition, it showed better results in Th-17 and Th-2 response (superiority). This study can be regarded as a springboard for further probes in booster pertussis vaccine development. UR - https://iji.sums.ac.ir/article_46744.html L1 - https://iji.sums.ac.ir/article_46744_04919b600e6ffeabc28541970a93a01a.pdf ER -